Candel Therapeutics has appointed Mark Sims as Chief Commercial Officer, effective July 6, 2026. He will lead commercial strategy and launch readiness for the Biologics License Application submission planned for the fourth quarter of 2026 and the estimated 2027 launch of aglatimagene besadenovec, the company's localized prostate cancer treatment. Sims previously served at AstraZeneca as Vice President and Global Franchise Head, directing commercial strategy for one of its largest business franchises. President and CEO Paul Peter Tak noted that intermediate- to high-risk localized prostate cancer represents a large market opportunity, with approximately 65,000 patients diagnosed annually in the United States who are candidates for radiotherapy-based treatment. Sims brings over 25 years of experience from roles at AstraZeneca, Novartis Idenix Pharmaceuticals, and Merck & Co.
Candel Therapeutics IncAppointment of experienced CCO to lead commercial strategy for upcoming BLA submission and launch of prostate cancer treatment.
AstraZeneca PLC
Merck & Company Inc
Novartis AG
Nuvalent Inc